ArticleHardwareX2024
mSLAb - An open-source masked stereolithography (mSLA) bioprinter.
Article in HardwareX, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AnyBio - An easy off-the-shelf masked stereolithography bioprinter conversion combined with radical-scavenging strategies.HardwareX · 2025Article
- The feasibility of 3D bioprinting for bone regeneration: key challenges and future directions.Regenerative medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D bioprinting is a tissue engineering approach using additive manufacturing to fabricate tissue equivalents for regenerative medicine or medical drug testing. For this purpose, biomaterials that provide the essential microenvironment to support the viability of cells integrated directly or seeded after printing are processed into three-dimensional (3D) structures. Compared to extrusion-based 3D printing, which is most commonly used in bioprinting, stereolithography (SLA) offers a higher printing resolution and faster processing speeds with a wide range of cell-friendly materials such as gelatin- or collagen-based hydrogels and SLA is, therefore, well suited to generate 3D tissue constructs. While there have been numerous publications of conversions and upgrades for extrusion-based printers, this is not the case for state-of-the-art SLA technology in bioprinting. The high cost of proprietary printers severely limits teaching and research in SLA bioprinting. With mSLAb, we present a low-cost and open-source high-resolution 3D bioprinter based on masked SLA (mSLA). mSLAb is based on an entry-level (€350) desktop mSLA printer (Phrozen Sonic Mini 4 K), equipped with temperature control and humidification of the printing chamber to enable the processing of cell-friendly hydrogels. Additionally, the build platform was redesigned for easy sample handling and microscopic analysis of the printed constructs. All modifications were done with off-the-shelf hardware and in-house designed 3D printed components, printed with the same printer that was being modified. We validated the system by printing macroscopic porous scaffolds as well as hollow channels from gelatin-based hydrogels as representative structures needed in tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.